Ilyas Sahin

Ilyas Sahin, M.D.

CLIN AST PROF

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: i.sahin@ufl.edu

About Ilyas Sahin

Dr. Ilyas Sahin is an esteemed Assistant Professor of Medicine at the University of Florida, where he specializes in gastroesophageal and hepatobiliary cancers. With an MD earned with High Honors from Hacettepe University Faculty of Medicine in Ankara, Turkey, Dr. Sahin has cultivated a distinguished career in internal medicine, hematology, and oncology. His postgraduate journey led him through residencies and fellowships at internationally recognized institutions, including Harvard University and Brown University.

As a board-certified professional in Internal Medicine, Medical Oncology, and Hematology, Dr. Sahin brings a depth of expertise to his clinical and research work. He has been a pivotal figure in numerous clinical trials, focusing on innovative treatments in his areas of specialization. Beyond his clinical endeavors, Dr. Sahin is a prolific contributor to medical literature, with over 50 publications to his name, underscoring his commitment to advancing medical knowledge.

In the academic realm, Dr. Sahin holds editorial and reviewer roles in several prestigious medical journals, reflecting his broad influence and respect in the medical community. Dr. Sahin’s dedication to his field is not only evident in his clinical and research accomplishments but also in his role as an educator and mentor, guiding the next generation of medical professionals at the University of Florida.

Accomplishments

Pilot Project Award
2020 · Cancer Center at Brown University

Board Certifications

  • Hematology
    American Board Of Internal Medicine
  • Internal Medicine
    American Board Of Internal Medicine
  • Oncology
    American Board Of Internal Medicine

Clinical Profile

Specialties
  • Gastroenterology
Areas of Interest
  • Esophageal cancer
  • Gastrointestinal cancer
  • Liver cancer – hepatocellular carcinoma
  • Stomach cancer

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-2070-9319

Publications

2023
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Future oncology (London, England). 19(27):1841-1851 [DOI] 10.2217/fon-2023-0256. [PMID] 37753702.
2023
Addendum: Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.
Oncotarget. 14 [DOI] 10.18632/oncotarget.28491. [PMID] 38085073.
2023
Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
Cancers. 15(6) [DOI] 10.3390/cancers15061808. [PMID] 36980692.
2023
Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis
Journal of Hepatocellular Carcinoma. Volume 10:1129-1141 [DOI] 10.2147/jhc.s417273.
2023
Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.
Oncotarget. 14:351-357 [DOI] 10.18632/oncotarget.28406. [PMID] 37068159.
2023
Mechanisms of drug resistance in HCC.
Hepatology (Baltimore, Md.). 79(4):926-940 [DOI] 10.1097/HEP.0000000000000237.
2023
Methylated ctDNA Quantification: Non-Invasive Approach to Monitoring Hepatocellular Carcinoma Burden.
Journal of the American College of Surgeons. 238(4):770-778 [DOI] 10.1097/XCS.0000000000000939. [PMID] 38146818.
2023
Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study
Cancers. 15(20) [DOI] 10.3390/cancers15205055. [PMID] 37894422.
2023
The Role of HER2 Status in the Biliary Tract Cancers
Cancers. 15(9) [DOI] 10.3390/cancers15092628. [PMID] 37174094.
2023
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer.
The lancet. Gastroenterology & hepatology. 8(3) [DOI] 10.1016/S2468-1253(22)00402-2. [PMID] 36773612.
2023
Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 29(5):1206-1217 [DOI] 10.1177/10781552231171079. [PMID] 37097888.
2022
Advanced Hepatocellular Carcinoma in Adults Without Cirrhosis: A Single-Institution Retrospective Review.
Journal of hepatocellular carcinoma. 9:1299-1307 [DOI] 10.2147/JHC.S384438. [PMID] 36567797.
2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Future oncology (London, England). [DOI] 10.2217/fon-2022-0392. [PMID] 36399037.
2022
Nivolumab in Esophageal Squamous-Cell Carcinoma.
The New England journal of medicine. 386(20):1958-1959 [DOI] 10.1056/NEJMc2202880. [PMID] 35584166.
2021
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Leukemia & lymphoma. 62(10):2457-2465 [DOI] 10.1080/10428194.2021.1919657. [PMID] 33993837.
2021
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.
Scientific reports. 11(1) [DOI] 10.1038/s41598-021-98760-9. [PMID] 34588522.
2021
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
Blood Advances. 5(24):5525-5535 [DOI] 10.1182/bloodadvances.2021004512. [PMID] 34551072.
2021
Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.
Oncotarget. 12(21):2131-2146 [DOI] 10.18632/oncotarget.28086. [PMID] 34676046.
2021
Strategies to sensitize cancer cells to immunotherapy.
Human vaccines & immunotherapeutics. 1-7 [DOI] 10.1080/21645515.2021.1891817. [PMID] 34019474.
2021
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
Frontiers in Oncology. 11 [DOI] 10.3389/fonc.2021.801379. [PMID] 34956912.
2021
Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers
International Journal of Molecular Sciences. 22(21) [DOI] 10.3390/ijms222111790. [PMID] 34769221.
2020
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
Cell death discovery. 6 [DOI] 10.1038/s41420-020-0292-1. [PMID] 32655895.
2020
Asciminib in Relapsed Chronic Myeloid Leukemia.
The New England journal of medicine. 382(14):1378-1379 [DOI] 10.1056/NEJMc2000116. [PMID] 32242375.
2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection.
Oncotarget. 11(46):4201-4223 [DOI] 10.18632/oncotarget.27799. [PMID] 33245731.
2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
bioRxiv : the preprint server for biology. [DOI] 10.1101/2020.08.02.230839. [PMID] 32793908.
2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.
Blood advances. 3(7):995-1002 [DOI] 10.1182/bloodadvances.2018028456. [PMID] 30940634.
2019
Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy.
British journal of haematology. 186(3):e31-e35 [DOI] 10.1111/bjh.15861. [PMID] 30859554.
2019
Erythrophagocytosis on bone marrow found in severe autoimmune hemolytic anemia with reticulocytopenia.
Blood. 134(21) [DOI] 10.1182/blood.2019002708.
2019
Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.
Cancer biology & therapy. 20(8):1047-1056 [DOI] 10.1080/15384047.2019.1595283. [PMID] 30975030.
2019
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
OncoTargets and therapy. 12:1085-1094 [DOI] 10.2147/OTT.S165615. [PMID] 30799938.
2019
Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy.
Integrative cancer therapies. 18 [DOI] 10.1177/1534735419835310. [PMID] 30897972.
2018
Androgen receptor-independent prostate cancer: an emerging clinical entity.
Cancer biology & therapy. 19(5):347-348 [DOI] 10.1080/15384047.2018.1423926. [PMID] 29333925.
2018
Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
The New England journal of medicine. 379(12) [DOI] 10.1056/NEJMc1809507. [PMID] 30260154.
2018
Refractoriness to red blood cell transfusion therapy due to hypersplenism.
Transfusion. 58(11):2513-2516 [DOI] 10.1111/trf.14876. [PMID] 30260482.
2016
Drug Delivery Approaches for the Treatment of Cervical Cancer.
Pharmaceutics. 8(3) [DOI] 10.3390/pharmaceutics8030023. [PMID] 27447664.
2015
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
Cell reports. 12(4):622-35 [DOI] 10.1016/j.celrep.2015.06.059. [PMID] 26190113.
2015
Early start of adjuvant chemotherapy in breast cancer.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 20(4) [PMID] 26416072.
2014
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Blood. 123(26):4120-31 [DOI] 10.1182/blood-2014-03-564583. [PMID] 24711662.
2014
CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.
Blood. 124(12):1905-14 [PMID] 25079359.
2014
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.
Blood cancer journal. 4 [DOI] 10.1038/bcj.2014.24. [PMID] 24769645.
2014
Pyk2 promotes tumor progression in multiple myeloma.
Blood. 124(17):2675-86 [DOI] 10.1182/blood-2014-03-563981. [PMID] 25217697.
2014
Role of endothelial progenitor cells in cancer progression.
Biochimica et biophysica acta. 1846(1):26-39 [DOI] 10.1016/j.bbcan.2014.03.005. [PMID] 24709008.
2014
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
American journal of hematology. 89(11):1030-6 [DOI] 10.1002/ajh.23814. [PMID] 25060991.
2014
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.
Blood. 124(11):1765-76 [DOI] 10.1182/blood-2014-03-560862. [PMID] 25061176.
2014
Waldenström macroglobulinemia: from biology to treatment.
Expert review of hematology. 7(1):157-68 [DOI] 10.1586/17474086.2014.871494. [PMID] 24405328.
2013
Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Medical oncology (Northwood, London, England). 30(3) [DOI] 10.1007/s12032-013-0615-7. [PMID] 23729267.
2013
The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression.
Leukemia. 27(4):961-4 [DOI] 10.1038/leu.2012.353. [PMID] 23212153.
2011
Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Medical oncology (Northwood, London, England). 28(4):1308-10 [DOI] 10.1007/s12032-010-9636-7. [PMID] 20668965.
2011
Sequential taxane and anthracycline-containing neo-adjuvant regimens; any rationale behind the sequence?
Breast (Edinburgh, Scotland). 20(3) [DOI] 10.1016/j.breast.2011.02.008. [PMID] 21371886.
2010
How can Nolvadex abolish arthralgia in women taking newer generic Tamoxifen preparations?
Breast (Edinburgh, Scotland). 19(5) [DOI] 10.1016/j.breast.2010.05.002. [PMID] 20554203.
2010
Management of polyorchidism: Surgery or conservative management?
Journal of human reproductive sciences. 3(3):162-3 [DOI] 10.4103/0974-1208.74166. [PMID] 21234184.
2010
Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
British journal of haematology. 151(5):530-1 [DOI] 10.1111/j.1365-2141.2010.08388.x. [PMID] 20880117.
2010
Possible mechanisms behind taxane-anthracycline sequencing.
The Lancet. Oncology. 11(6):514-5 [DOI] 10.1016/S1470-2045(10)70067-X. [PMID] 20522380.

Grants

Aug 2023 ACTIVE
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Role: Principal Investigator
Funding: CATALYST CLINICAL RESEARCH via COMPASS THERAPEUTICS
May 2023 ACTIVE
Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 as a Single Agent and in Combination With Standard of Care in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I )
Role: Principal Investigator
Funding: PRECISION FOR MEDICINE via OMEGA THERAPEUTICS
May 2023 – Oct 2023
Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 as a Single Agent and in Combination With Standard of Care in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I )
Role: Principal Investigator
Funding: PRECISION FOR MEDICINE via OMEGA THERAPEUTICS
Jan 2023 ACTIVE
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Dec 2022 ACTIVE
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Sep 2022 – Dec 2023
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Role: Principal Investigator
Funding: *CLINIPACE INC via SURFACE ONCOLOGY
Apr 2022 ACTIVE
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
i.sahin@ufl.edu
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
PO Box 100278
GAINESVILLE FL 32610